Biomaterial Database

Myalgias in human immunodeficiency virus-infected patients. 1989

D Buskila, and P Langevitz

UI	MeSH Term	Description	Entries
D009135	Muscular Diseases	Acquired, familial, and congenital disorders of SKELETAL MUSCLE and SMOOTH MUSCLE.	Muscle Disorders,Myopathies,Myopathic Conditions,Muscle Disorder,Muscular Disease,Myopathic Condition,Myopathy
D006801	Humans	Members of the species Homo sapiens.	Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000163	Acquired Immunodeficiency Syndrome	An acquired defect of cellular immunity associated with infection by the human immunodeficiency virus (HIV), a CD4-positive T-lymphocyte count under 200 cells/microliter or less than 14% of total lymphocytes, and increased susceptibility to opportunistic infections and malignant neoplasms. Clinical manifestations also include emaciation (wasting) and dementia. These elements reflect criteria for AIDS as defined by the CDC in 1993.	AIDS,Immunodeficiency Syndrome, Acquired,Immunologic Deficiency Syndrome, Acquired,Acquired Immune Deficiency Syndrome,Acquired Immuno-Deficiency Syndrome,Acquired Immuno Deficiency Syndrome,Acquired Immuno-Deficiency Syndromes,Acquired Immunodeficiency Syndromes,Immuno-Deficiency Syndrome, Acquired,Immuno-Deficiency Syndromes, Acquired,Immunodeficiency Syndromes, Acquired,Syndrome, Acquired Immuno-Deficiency,Syndrome, Acquired Immunodeficiency,Syndromes, Acquired Immuno-Deficiency,Syndromes, Acquired Immunodeficiency
D015215	Zidovudine	A dideoxynucleoside compound in which the 3'-hydroxy group on the sugar moiety has been replaced by an azido group. This modification prevents the formation of phosphodiester linkages which are needed for the completion of nucleic acid chains. The compound is a potent inhibitor of HIV replication, acting as a chain-terminator of viral DNA during reverse transcription. It improves immunologic function, partially reverses the HIV-induced neurological dysfunction, and improves certain other clinical abnormalities associated with AIDS. Its principal toxic effect is dose-dependent suppression of bone marrow, resulting in anemia and leukopenia.	AZT (Antiviral),Azidothymidine,3'-Azido-2',3'-Dideoxythymidine,3'-Azido-3'-deoxythymidine,AZT Antiviral,AZT, Antiviral,BW A509U,BWA-509U,Retrovir,3' Azido 2',3' Dideoxythymidine,3' Azido 3' deoxythymidine,Antiviral AZT,BWA 509U,BWA509U

Related Publications

D Buskila, and P Langevitz

Coccidioidomycosis in human immunodeficiency virus-infected patients.

November 1990, The Journal of infectious diseases,

D Buskila, and P Langevitz

[Pneumothorax in human immunodeficiency virus infected patients].

October 2008, Cirugia espanola,

D Buskila, and P Langevitz

BK virus infection in human immunodeficiency virus-infected patients.

July 2012, European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology,

D Buskila, and P Langevitz

Molluscum contagiosum in human immunodeficiency virus infected patients.

January 2008, Indian journal of dental research : official publication of Indian Society for Dental Research,

D Buskila, and P Langevitz

Cochlear implantation in human immunodeficiency virus-infected patients.

November 2003, Otology & neurotology : official publication of the American Otological Society, American Neurotology Society [and] European Academy of Otology and Neurotology,

D Buskila, and P Langevitz

Antiretroviral hepatotoxicity in human immunodeficiency virus-infected patients.

October 2001, Alimentary pharmacology & therapeutics,

D Buskila, and P Langevitz

Neurosyphilis in patients infected with human immunodeficiency virus.

February 1990, Annals of neurology,

D Buskila, and P Langevitz

Cardiovascular manifestations in human immunodeficiency virus-infected patients.

September 2008, The American journal of cardiology,

D Buskila, and P Langevitz

Transfusion practices in human immunodeficiency virus-infected patients.

July 1995, Transfusion,